Haug Partners LLP

Contact
Share
Info
745 Fifth Avenue
10th Floor
New York, NY 10151, United States
Phone: 212.588.0800
Areas Of Practice
  • Alternative Dispute Resolution (ADR)
  • Antitrust & Trade Regulation
  • Intellectual Property
  • International Law & Trade
  • Mergers & Acquisitions
  • Science, Computers, & Tech
Locations
Other U.S. Locations
  • D.C.
  • Massachusetts
  • New York
Number of Attorneys
51-99 Attorneys

U.S. Merger-Clearance Update: The Revival of Structural Remedies

Under the Trump administration, the U.S. Federal Trade Commission (“FTC”) and the Antitrust Division of the U.S. Department of Justice (“DOJ Antitrust”) have signaled a significant policy shift in merger clearance, projecting a… more
 /  Antitrust & Trade Regulation, Mergers & Acquisitions

In CRISPR Patent Dispute, the Federal Circuit Clarifies the Conception and Written Description Standards

On May 12, 2025, the Federal Circuit issued a decision in Regents of the Univ. of California v. Broad Inst., Inc.1 concerning the ongoing priority dispute relating to competing inventor groups for the CRISPR-Cas9 eukaryotic gene… more
 /  Intellectual Property, Science, Computers, & Technology

FTC Issues a Third Round of Warning Letters Over Improper Orange Book Listings

On May 21, 2025, the Federal Trade Commission (FTC) renewed its efforts to challenge pharmaceutical manufacturers that have allegedly listed patents improperly in the Food and Drug Administration’s (FDA) publication of “Approved… more
 /  Antitrust & Trade Regulation, Health, Intellectual Property

Settled Expectations: How the PTAB’s New Discretionary Denial Framework Is Reshaping IPR Strategy

In a recent article, Haug Partners previewed that the impact of the Patent Trial and Appeal Board’s (PTAB) new bifurcated approach to discretionary denial requests would depend on how the new Acting USPTO Director, Coke Morgan… more
 /  Administrative Law, Intellectual Property

Regeneron Pharmaceuticals, Inc. v. Amgen Inc.: Jury Finds Rebate Offers on Bundled Drugs in Exchange for Exclusive Formulary Placement Violate Antitrust Laws

On May 15, 2025, a federal jury in Delaware district court determined that Defendant Amgen Inc. (“Amgen”) violated antitrust and tort laws, and awarded $406.8 million in damages to Plaintiff Regeneron Pharmaceuticals, Inc… more
 /  Antitrust & Trade Regulation, Business Torts, Civil Procedure, Health

Federal Circuit Provides Further Guidance on Obvious Type Double Patenting For Patents Sharing Common Priority

On June 9th, 2025, the Federal Circuit issued a decision in Acadia Pharms. Inc. v. Aurobindo Pharma Ltd., affirming the district court’s grant of summary judgment of no invalidity for obviousness-type double patenting (OTDP)… more
 /  Civil Procedure, Intellectual Property

License to Exclude? Federal Circuit Emphasizes Need for Reliability of Patent Damages Experts in EcoFactor Inc. v. Google LLC

On May 21, 2025, in an en banc decision, the U.S. Court of Appeals for the Federal Circuit vacated its earlier panel ruling and remanded the case of EcoFactor Inc. v. Google LLC for further proceedings. The court focused on the… more
 /  Civil Procedure, Commercial Law & Contracts, Intellectual Property

Federal Circuit Clarifies Safe Harbor from Injunctive Relief in Jazz v. Avadel

On May 6, 2025, the U.S. Court of Appeals for the Federal Circuit refined the boundaries of injunctive relief under the Hatch-Waxman Act in its precedential opinion in Jazz Pharms., Inc. v. Avadel CNS Pharms. The decision… more
 /  Administrative Law, Health, Intellectual Property

The PTAB’s Overhaul of Its Discretionary Denial Procedures Signals a Pro-Patent Pivot

Since Acting USPTO Director Coke Morgan Stewart took office in 2025, the Patent Trial and Appeal Board (PTAB) has overhauled its discretionary denial procedures for inter partes reviews (IPRs) and post-grant reviews (PGRs)… more
 /  Administrative Law, Civil Procedure, Intellectual Property

The Application of Generic Machine Learning to New Data Environments Requires “Something More” to be Patent Eligible

On April 18, 2025, the Federal Circuit issued an opinion in Recentive Analytics, Inc. v. Fox Corp. addressing for the first time whether patents that claim no more than the application of generic machine learning to a new data… more
 /  Intellectual Property, Science, Computers, & Technology

Federal Circuit Affirms Presumption of Separateness in Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc. et al., C.A. No. 24-2351 (Fed. Cir. Mar. 14, 2025)

In a formulation claim, if elements are listed separately, does this necessarily entail that those elements are “separate and distinct components”?  This was the question before the district court in Regeneron Pharmaceuticals,… more
 /  Health, Intellectual Property, Science, Computers, & Technology

Defend & Deduct: How the Federal Circuit's Actavis Decision Changes Tax Implications for ANDA Filers

In Actavis Labs. FL, Inc. v. U.S.  (“Actavis”), a recent precedential decision, the Federal Circuit answered an important practical question regarding the interplay between the Hatch-Waxman Act and the Internal Revenue Code: are… more
 /  Health, Intellectual Property, Taxation

Federal Circuit Limits Use of PTAB Unpatentability Rulings to Estop Patentees From Asserting Claims

On February 10, 2025, the Federal Circuit issued a precedential decision in Kroy IP Holdings, LLC v. Groupon, Inc., where the Court held that a “a prior final written decision of the [PTAB] of unpatentability on separate patent… more
 /  Administrative Law, Civil Procedure, Intellectual Property

The Sole Meaning of “Solely”: Supreme Court Denies Certiorari on Edward Life Sciences v. Meril Life Sciences Pvt. Ltd. and Permits a Broad Interpretation of the Hatch-Waxman Safe Harbor Provision

This month the Supreme Court denied certiorari on Edwards Lifesciences Corp. v. Meril Life Sciences Pvt. Ltd., and in doing so, seemingly indicated its support for a broad interpretation of the Hatch-Waxman safe harbor provision… more
 /  Administrative Law, Civil Procedure, Health, Intellectual Property

Federal Circuit Addresses Two Key Requirements of On-Sale Bar of Pre-AIA Section 102(b)

The Federal Circuit’s recent precedential decision in Crown Packaging Technology Inc. v. Belvac Production Machinery, Inc. is noteworthy because it discusses two key requirements of the on-sale bar prong of pre-AIA section… more
 /  Civil Procedure, Commercial Law & Contracts, Intellectual Property
Showing 1-15 of 208 Results
/
View per page
Page: of 14
This profile may constitute attorney advertising. Prior results do not guarantee a similar outcome. Any correspondence with this profile holder does not constitute a client/attorney relationship. Neither the content on this profile nor transmissions between you and the profile holder through this profile are intended to provide legal or other advice or to create an attorney-client relationship.

"My best business intelligence,
in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide